US
Updated
Reviewed by Chandani Patel
US AI in Drug Repurposing Market Industry Trends and Forecast to 2034: Segmented by (Approach, Indication, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $263.1 Mn.
Canada at 22.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.10 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $219.1 Mn | — | — |
| 2025 (base) | $263.1 Mn | +$44.0 Mn | — |
| 2026 (forecast) | $316.0 Mn | +$52.9 Mn | +20.1% |
| 2027 (forecast) | $379.5 Mn | +$63.5 Mn | +44.2% |
| 2028 (forecast) | $455.8 Mn | +$76.3 Mn | +73.2% |
| 2029 (forecast) | $547.4 Mn | +$91.6 Mn | +108.1% |
| 2030 (forecast) | $657.4 Mn | +$110.0 Mn | +149.9% |
| 2031 (forecast) | $789.5 Mn | +$132.1 Mn | +200.1% |
| 2032 (forecast) | $948.2 Mn | +$158.7 Mn | +260.4% |
| 2033 (forecast) | $1.14 Bn | +$190.6 Mn | +332.9% |
| 2034 (forecast) | $1.37 Bn | +$228.9 Mn | +419.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$263.1 Mn
Canada
$54.3 Mn
China
$53.8 Mn
Japan
$37.0 Mn
Germany
$24.4 Mn
Brazil
$16.0 Mn
Italy
$15.8 Mn
UK
$15.2 Mn
France
$13.8 Mn
Ecuador
$12.3 Mn
India
$11.5 Mn
Spain
$9.8 Mn
Mexico
$8.7 Mn
Saudi Arabia
$8.8 Mn
Australia
$8.0 Mn
Russia
$6.7 Mn
New Zealand
$5.7 Mn
South Africa
$4.4 Mn
UAE
$2.6 Mn
Egypt
$1.7 Mn
Philippines
$1.2 Mn
Hong Kong
$0.9 Mn
Malaysia
$0.9 Mn
Singapore
$0.8 Mn
Thailand
$0.6 Mn
Kenya
$0.5 Mn
| Market size, 2025 | $263.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.37 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 20.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Artificial Intelligence in Drug Repurposing |
| Segments | Approach and indication (see all) |
| Key players | BenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals, Every Cure (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AI in drug repurposing searches data to find new uses for existing medicines, cutting the time and cost of development.
Key segments of the AI in Drug Repurposing market include approach (Knowledge Graphs, Machine Learning on Omics and Real-World Data Mining) and indication (Rare Diseases, Oncology and Infectious Diseases).
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.
Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Drug Repurposing market strong growth, including in emerging health systems.
Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Drug Repurposing market.
The AI in Drug Repurposing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AI in Drug Repurposing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in AI in Drug Repurposing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
Digital Health · US
Digital Health · US
Digital Health · US
Digital Health · US
Digital Health · US
Digital Health · US